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PRELIMINARY DRUG STUDIES 
FRENTIZOLE THERAPY OF 
ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS 
DONALD R. KAY, THOMAS V. VALENTINE, SARA E. WALKER, MERILEE H. VALENTINE, and 
GILES G. BOLE 
Frentizole is a benzimidazoleurea that has immu- 
nosuppressive properties in mice. Eleven steroid-treated 
patients with active systemic lupus erythematosus re- 
ceived frentizole (150-350 mg/day) in combination with 
stable or decreasing doses of prednisone in an open la- 
bel trial. Nine patients completed at least one 21- to 75- 
day course of therapy with this drug. Clinical parame- 
ters of disease improved in 8 of these 9 patients. Mean 
DNA binding decreased by 28%, mean CH50 increased 
by 20%, and mean absolute lymphocyte and T cell 
counts decreased by 25-2696. Granulocytopenia was not 
observed. Three patients developed reversible hepatic 
toxicity. Clinical and serologic improvement was noted 
in 3 patients who accepted a second W a y  course of 
frentizole therapy. 
Frentizole, a benzimidazoleurea [ 1 -(6-methoxy- 
2-benzothiazolyl)-3-phenyl urea, Compound 536 16, Eli 
Lilly Company], was developed to provide an alterna- 
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tive to cytotoxic antineoplastic agents which are used to 
treat selected autoimmune diseases (1). This drug was 
selected for testing in humans after initial screening 
showed that it had immunosuppressive properties in 
mice (24). In the NZB/NZW mouse model of systemic 
lupus erythematosus (SLE), therapy with frentizole pro- 
longed life and decreased proteinuria (43). Frentizole 
had a therapeutic index 3 to 7 times greater than cyto- 
toxic antineoplastic drugs and was synergistic with cor- 
tisone (43). When frentizole was given to mice in a dose 
greater than the amount needed to cause immuno- 
suppression, the incidence of infection was not in- 
creased (6). In experimental animals, therapy with 
frentizole was associated with anemia, hepatic toxicity, 
and thyroid toxicity after large doses were given over an 
extended period of time (5,7). The effectiveness of this 
drug as an immunosuppressive agent and its relatively 
low toxicity in animals prompted us to design a trial to 
determine if frentizole had immunosuppressive and/or 
toxic effects in patients with SLE. 
PATIENTS AND METHODS 
Eleven adult SLE patients were enrolled in the trial 
(Table 1). Each patient met the five predetermined selection 
criteria outlined in Table 2. Patients with one or more of the 
following findings were excluded: central nervous system 
lupus; lupus pneumonitis; infection; pregnancy or lactation; 
earlier cytotoxic drug therapy; uncompensated hemolytic 
anemia; hematocrit less than 26% or hemoglobin less than 9 
gm/ 100 ml; platelet count less than 80,000/mm3; serum creati- 
nine greater than 3 mg/100 ml; blood urea nitrogen greater 
than 40 mg/100 ml; creatinine clearance less than 50 ml/min- 
Ute. 
Three protocols were utilized in this trial. In each pro- 
tocol, patients were maintained on previous doses of predni- 
sone, and frentizole was added in a single daily dose for a pre- 
determined length of time. Other concomitantly administered 
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Prednisone dose mg/day 
Other drug 
Disease Initial dose therapy Frentizole 
duration No. of (duration, Previous (duration, ____ 
Agehex (years) criteria* days) dose months)+ m g / k  mg/day Days 
47/F 6 10 20 ( 1  14) 22 None 2.2 200 21 
30/F 8 I I  22 (60) 25 A(6). H(8) 3.0 150 21 
47/F 5 7 15 (300) 30 M(36). P(12). H(12) 5.0 350 1 1  
22/F 2 9 40 (30) 42 None 6.0 350 21 
B 
28 + 90$ 
42 + 90$ 
4.0 225 
4.0 275 8 + 5  
4.0 250 
4.0 250 42 
45 (60) 30 None 
20 (30) 15 A( 14), H(8) 
30 (90) 35 M(4), C(4) 
30 (360) 0 None 
5 28/F 5 6 
6 35/F 8 6 
7 22/F 2 7 
8 25/F 3 7 
c 
9 I8/F 5 9 60 (210) 0 None 4.0 225 15 
10 22/F 5 10 60 (60) 30 None 4.0 200 63 + 90$ 
I I  33/M 1 5 35 (120) 30 P(5). W5). C(5) 4.0 350 63 
* American Rheumatism Association criteria for the classification of SLE (8). 
t A = aspirin; H = hydroxychloroquine; M = methyldopa; P = propranolol; C = chlorthalidone. 
$ After the initial course of frentizole was completed, 3 patients experienced flares of SLE. They received additional 90-day courses of therapy 
with frentizole, 4-6 mg/kg/day. 
drugs and their doses remained constant throughout the study 
(Table I ) .  Protocol A was designed as a dose ranging study to 
determine the effective and/or toxic doses of frentizole. Four 
protocol A patients were admitted to the University of Mich- 
igan Clinical Research Center to receive frentizole for 2 I 
days. Patient #3 experienced dysfunctional uterine bleeding 
on the tenth day of frentizole therapy. She was treated with 
progesterone and uterine dilitation and curettage, her predni- 
sone dose was increased to 60 mg/day, and she was dropped 
from the study. A bone marrow examination and coagulation 
studies showed no evidence of frentizole toxicity. Hepatic tox- 
icity in patient #4, who received 6 mg/kg/day, led us to re- 
duce the dose for patients in protocols B and C to 4 mg/kg/ 
day. Patients in protocols R and C were hospitalized in the 
Clinical Research Center for approximately I week at the be- 
ginning and for 3 days at the end of an initial course of frenti- 
zole therapy. In protocol B (Table I ) ,  4 patients were sched- 
uled to receive frentizole for 42 days. However, 2 patients (#5 
and #6) developed hepatotoxicity and patient 8 6  was 
dropped from the trial (described in Results). In protocol C 
(Table I). 2 patients were treated with frentizole for 63 days 
and I patient received frentizole for 75 days. 
In protocols A and B, doses of prednisone were not 
changed during frentizole therapy; however, beginning I week 
after frentizole treatment was stopped, prednisone doses could 
be tapered at the discretion of the investigator. In protocol C, 
the prednisone doses could be tapered after the initial 21 days 
of frentizole therapy. Patients who experienced lupus flares in 
the 90-day period following termination of frentizole therapy 
were eligible for retreatment if they met the selection criteria. 
Patients #4, #7, and #I0 received frentizole (4-6 mg/kg/day) 
for an additional 90-day period (described in Results). 
Each patient had pre- and posttreatment studies in- 
cluding chest roentgenograms, electrocardiograms, bone mar- 
row aspirates and biopsies, and tests for delayed hyper- 
sensitivity to 0. I ml intracutaneous injections of five skin test 
antigens (Cundidu, PPD intermediate strength, streptokinase 
plus streptodornase, dermatophyton extract, and mumps anti- 
gen). At intervals of 3-7 days during the treatment period, pa- 
tients had complete blood counts, urinalyses, and measure- 
ments of  serum Na, K, Cl, HCO,, blood urea nitrogen, 
creatinine, calcium, phosphorus, glucose, albumin, uric acid, 
bilirubin, alkaline phosphatase, serum glutamic pyruvate 
transaminase (SGPT), serum glutamic oxaloacetic trans- 
aminase (SGOT), lactic acid dehydrogenase (LDH), and tri- 
glycerides. Twenty-four hour urine content of creatinine and 
protein was measured weekly. At intervals of 1, 2, or 4 weeks, 
the following tests were obtained: serum IgG, IgM, IgA, rheu- 
matoid factor (latex agglutination method), direct Coombs 
test, indirect immunofluorescent antinuclear antibody test in 
Table 2. Criteria for selection of trial participants 
1. Four or more AKA classification criteria for SLE (8)' 
2. Two or more clinical manifestations of active SLE present for at 
least 30 days: 
a. appearance or progression of SLE rash 
b. appearance or progression of cutaneous vasculitis 
c. unexplained (nonbacterial) fever (> 37.8"C) 
d. pleurisy or pericarditis 
e. severe myalgias, arthralgias, or synovitis 
f. appearance of proteinuria greater than 2 gm/24 hours 
3. Serum total hemolytic complement activity less than 80 CH50 
units (normal 104-188) (9) and/or antiDNA antibody levels 
greater than 30% (normal &20% binding in modified Farr assay) 
(10) 
4. Stable prednisone dose of 15 mg/day or greater for at least 30 days 
5. Presence of corticosteroid side effects 
* ARA = American Rheumatism Association. 
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Table 3. Clinical findings of active SLE in 9 patients treated with frentizole 
End of therapy. After end of therapy (1 month) 
Before* Worse Better Absent Unchanged Worse Better Absent Unchanged 
Skin? 8 0 4 2 2 0 3 3 2 
MucosaS 4 0 0 3 1 0 0 3 0 
Pleurisy 1 0 0 1 0 0 0 1 0 
Joints1 9 1 4 1 3 1 4 1 3 
* Numbers in table are numbers of patients. 
t Reappearance or progression of discoid lesions, other SLE rash, and/or cutaneous vasculitis. + Oral or nasal mucosal ulcerations. 
1 Signs of joint inflammation. 
titered serum, antiDNA antibody (by modified Farr tech- 
nique), CH50, C3, C4, thyroid antibodies, T and B lympho- 
cyte enumeration (sheep red blood cell rosette formation and 
direct immunofluorescence of surface immunoglobulins, re- 
spectively), and lymphocyte stimulation assays with phytohe- 
magglutinin, pokeweed mitogen, and concanavalin A. P val- 
ues were derived by application of the paired t test. 
Each patient was examined by one of the investigators 
(TVV, SEW, DRK) at least once a week during the trial. 
RESULTS 
Nine patients completed at least one 21-day 
course of frentizole. Table 3 records signs of clinical 
SLE activity before and after an initial course of frenti- 
zole therapy. Clinical improvement was noted in 8 of 
the 9 patients. Figure 1 summarizes serum DNA bind- 
ing values before, at the end of the initial course, and at 
1,4, and 5 months after completion of the initial course 
of frentizole therapy. The mean value at the beginning 
of treatment was 47%. After the treatment period, mean 
DNA binding fell to 34% (P < 0.05). In 7 of the 9 pa 
tients, decreased levels of DNA binding persisted for at 
least 1 month after frentizole therapy was discontinued. 
Mean serum CH50 values before and after treat- 
ment are presented in Figure 2. At the end of the initial 
course of frentizole therapy, mean CH50 had increased 
from 101 to 120 CH50 units (P < 0.025). One month af- 
ter frentizole therapy was stopped, mean serum hemo- 
lytic complement activity was 127 CH50 units. The 
largest increases in CH50 levels were noted in the pa- 
tients who had abnormally low pretreatment levels @a- 
tients #1, 2, 7, 10, ll).  CH50 levels in these patients in- 
creased from a mean pretreatment value of 73 to 112 
after the initial course of frentizole (P < 0.001), and in- 
creased CH50 was maintained during the subsequent 
month. Changes in mean levels of C3 and C4 (Table 4) 
paralleled changes in CH50 levels. 
Mean serum levels of IgG decreased following 
frentizole therapy, while IgA and IgM levels remained 
unchanged. 
No patient became leukopenic during or after 
frentizole therapy. One patient (#2) had a low leuko- 
cyte count of 3,750 cells/mrn' at the beginning of treat- 
ment. Subsequently, the leukocyte count increased dur- 
ing treatment to 4,250 cells/mm3. One month after 
frentizole therapy was stopped, the leukocyte count was 
5,250 cells/mm3. Although total white blood cell counts 
remained essentially stable in all patients, total lympho- 
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Figure 1. This graph illustrates DNA binding immediately before 
frentizole therapy, at the end of the initial 21- to 75-day course, and 1, 
4, and 5 months after completion of initial course of frentizole. Solid 
lines represent times the patients were receiving frentizole and broken 
lines indicate times the patients were not receiving this drug. Each 
point on the graph represents the mean of two determinations. 
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. in doses were guided by the investigators’ assessments 
of disease activity and utilized clinical findings as well 
as serologic parameters (DNA binding activity and 
serum levels of CH50). The prednisone doses were re- 
duced in 8 of the 9 patients during and following frenti- 
zole therapy. 
Hepatotoxicity in association with frentizole 
therapy appeared in 3 of the 11 patients who partici- 
pated in this study. This complication was detected in 
each by an abrupt increase in the serum levels of SGPT 
and SGOT occurring 11 to 25 days after initiation of 
treatment. Patient #4 had normal SGPT, SGOT, and 
LDH values after 14 days of therapy with frentizole, 6 
mg/kg/day. Four days later SGPT was 2200, SGOT 
was 71, and LDH was 271 IU/liter. Frentizole was 
stopped on day 2 1. SGOT and LDH levels returned to 
the normal range within 7 days, and SGPT returned to 
normal 34 days after the drug was stopped. During the 6 
*+. 
I 
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Figure 2. CH50 levels for the 9 SLE patients who completed at least 
one course of frentizole therapy. This figure illustrates CH50 immedi- 
ately before frentizole therapy was started (PRE), at the end of the 
initial 21- to 75-day frentizole course (END), and 1, 4, and 5 months 
after completion of the initial course of frentizole. Solid lines repre- 
sent times the patients were receiving frentizole and broken lines in- 
dicate times the patients were not receiving this drug. 
phocyte count decreased by 25% during frentizole ther- 
apy, and this was maintained for the month following 
treatment (Table 4). Mean granulocyte counts increased 
in proportion to the decrease in mean lymphocyte 
counts. 
Decreases in serum antinuclear antibody titers in 
7 of the 9 patients paralleled decreases in serum DNA 
binding activity. Frentizole therapy was not associated 
with changes in Coombs tests or rheumatoid factor ti- 
ters. No consistent changes were noted in responses to 
skin test antigens and no patient became anergic during 
or following treatment. Peripheral B cells and T cells 
were not decreased, and consistent changes in lympho- 
cyte mitogenic responses were not noted. Chest roent- 
genograms, electrocardiograms, bone marrow aspirates, 
urine sediments, and creatinine clearances were un- 
changed. Infections did not develop in any of the pa- 
tients during or following frentizole therapy. There was 
no evidence of toxicity involving bone marrow, periph- 
eral blood, or thyroid. Hepatotoxicity was detected in 3 
patients (discussed below). 
Figure 3 depicts prednisone doses over a mini- 
mum period of 7 months for each of the 9 patients who 
completed at least one course of frentizole. Alterations 
months following this study, patient #4 remained in 
clinical and serologic remission and the prednisone dose 
was decreased from 40 to 11 mg/day. Patient #5 experi- 
enced hepatotoxicity and had an elevated SGPT value 
(264 IU/liter) on the twenty-fifth day of therapy with 
frentizole, 4 mg/kg/day. The drug was stopped on day 
28; at that time, SGOT was minimally elevated (38 IU/ 
liter). Thirty-two days after frentizole was discontinued, 
SGPT returned to normal. Patient #5 was subsequently 
retreated with frentizole for 6 months and no hepato- 
toxicity was observed. Patient #6 developed fever, ma- 
Table 4. Complement, immunoglobulin, and peripheral blood 
leukocyte levels before, at the end, and 1 month after frentizole 
therapy in 9 patients with SLE 
One month 
Before* End after end 
c 3  








% T lymphocytes 
% B lymphocytes 
Platelets 
85.0 f 2.0 109.0 f 2.0t 107.0 f I . O t  
14.0 & 1.0 19.0 f l .O+ 20.0 f I.O+ 
1020.0 f 6.0 966.0 f 7.0 950.0 f 6.09 
167.0 f 2.0 160.0 f 2.0 163.0 f 2.0 
288.0 & 2.0 288.0 f 2.0 296.0 & 2.0 
9.2 f 1.0 9.4 f 1.1 9.2 f 0.9 
2.3 f 0.4 1.7 f 0.3 1.8 f 0.3 
0.9 f 0.2 1.1 f 0.2 0.8 f 0.2 
0.1 f 0.05 0.1 f 0.02 0.1 f 0.03 
51.8 f 2.7 41.9 f 4.2 51.7 & 6.3 
5.8 f 1.2 8.7 & 2.8 6.9 f 1.9 
270.0 f 99.0 31 1.0 & 118.0$ 287.0 f 100.0 
* Mean f SE. Normal values: C3 99-192, C4 1749, IgG 564-1765, 
IgM 53-375, IgA 85-385 mg/100 ml; leukocytes 4.0-10.0, lympho- 
cytes 0.8-5.0, T lymphocytes 0.5-3.6, B lymphocytes 0.02-0.4 x lo3 
cells/mm’; % T lymphocytes 57-72, % B lymphocytes 2-9; platelets 
200-100 x 103 cells/mm3. 
t Compared to pretreatment value, P < 0.001. + Compared to pretreatment value, P < 0.05. 
5 Compared to pretreatment value, P < 0.025. 
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Figure 3. Daily prednisone doses for each of the 9 SLE patients who completed at least one course of frentizole. 
Solid lines represent times the patients were receiving frentizole. Broken lines indicate periods when frentizole 
was not given. 
laise, nausea, and diarrhea on day 8 of treatment and 
she elected to discontinue the drug. Three days later, 
her SGPT, SGOT, and LDH levels rose to 665,393, and 
540 IU/liter, respectively. The patient’s symptoms sub- 
sided after 4 days, and SGOT and LDH values returned 
to normal 16 days after frentizole was stopped. During 
retreatment with frentizole, definite increases in SGPT, 
SGOT, and LDH levels were seen. Frentizole therapy 
was stopped, and liver function tests returned to normal 
after 16 days. These 3 patients had no previous history 
of aspirin-induced hepatitis or other liver disease. In 
each case, tests for the presence of hepatitis B surface 
antigen and antibody to hepatitis B surface antigen 
were negative. Liver biopsies were not performed. 
Three patients (#5, 7, and 10) were retreated 
with frentizole after clinical and serologic SLE activity 
appeared one or more months after the completion of 
the initial course of therapy. One month after frentizole 
was discontinued, skin rash, synovitis, and elevated 
serum DNA binding (39%) were observed in patient #5. 
After 90 days of additional treatment, there was no clin- 
ical SLE activity, and the daily prednisone dose had 
been tapered from 45 to 27.5 mg/day (Figure 3). The 
patient continued to receive frentizole at a daily dose of 
250 mg in a separate protocol for an additional 98 days. 
A further decrease in prednisone dose was achieved 
(Figure 3), and there was no evidence of recurrent he- 
patotoxicity. Patient #7 was also retreated with frenti- 
zole for an additional 90 days. One year before the 
study began, she was treated with prednisone, 60 mg/ 
day to control biopsy-proven diffuse proliferative glo- 
merulonephritis. Prednisone was tapered to 30 mg/day, 
and a lupus flare occurred with cutaneous vasculitis, 
synovitis, elevated serum DNA binding (93%), de- 
pressed CH50 (82 CH50 units), hematuria, and neph- 
rotic syndrome. During the initial course of frentizole 
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therapy, cutaneous vasculitis resolved. DNA binding 
fell to 38%, and CH50 increased to 155 CH50 units. A 
second course of frentizole therapy was not associated 
with clinical or serologic toxicity. Creatinine clearance 
was unchanged, proteinuria decreased from 6.5 to 0.9 
gm/24 hours, hematuria decreased, and clinical im- 
provement was maintained. Patient #I0 was the third 
patient to receive a second course of frentizole therapy. 
When she first entered the study, the prednisone dose 
was 60 mg/day. Signs of active SLE included a malar 
rash, cutaneous vasculitis, oral ulcers, and synovitis. 
During 63 days of frentizole therapy, the skin lesions, 
oral ulcers, and synovitis resolved. DNA binding de- 
creased from 56 to 30%, and CH50 increased from 74 to 
106 CH50 units. The prednisone dose was tapered to 45 
mg/day. Six weeks after frentizole therapy was stopped, 
the malar rash, cutaneous vasculitis, and synovitis reap- 
peared. Frentizole therapy was restarted at a dose of 4 
mg/kg/day and later increased to 6 mg/kg/day. The 
skin lesions and synovitis resolved, antiDNA was 31%, 
and CH5O increased to I I 1  units. The prednisone dose 
was reduced successfully to 15 mg/day. Frentizole tox- 
icity was not observed. 
DISCUSSION 
This report describes the first Phase I1 open label 
trial of frentizole in patients with active SLE. The pro- 
tocols were designed to permit ethical evaluation of 
frentizole in active SLE patients who were taking toxic 
but ineffective daily doses of prednisone. Nine of the 1 1  
patients who entered this trial completed an initial 
course of frentizole and therefore represent cases that 
could be evaluated concerning the potential therapeutic 
efficacy of this drug. 
Clinical improvement was noted in 8 of the 9 pa- 
tients who completed an initial course of frentizole. Fa- 
vorable changes in clinical and laboratory parameters 
of active SLE were first detected 17 to 39 days after the 
experimental drug was given. Cumulative doses at the 
times of improvement ranged from 3.2 to 8.7 gm. 
Frentizole and cortisol were synergistic in sup- 
pression of mouse antibody response to sheep red blood 
cells (5). It cannot be concluded that similar synergism 
occurred in the patients who participated in this trial. 
However, the significant reductions in mean prednisone 
dosage which were achieved during and after frentizole 
therapy suggested that this drug might have a steroid- 
sparing effect. 
Frentizole therapy did not decrease autoimmune 
responses consistently in patients with active SLE. De- 
creases of DNA binding, ANA titers, and serum IgG 
levels during the initial 21- to 75-day courses of therapy 
may have resulted from spontaneous improvement of 
disease or concomitant administration of prednisone. 
Frentizole therapy did not depress cell mediated immu- 
nity. There was a trend to suppression of peripheral 
lymphocytes and T lymphocytes in patients treated with 
frentizole; however, skin test responses to a standard 
battery of antigens were not decreased. Furthermore, 
frentizole therapy did not correlate with changes in lym- 
phocyte responses to mitogenic stimulation. Our experi- 
ence was not consistent with the findings of other inves- 
tigators who reported that in vitro incubation of human 
lymphocytes with frentizole inhibited blastogenic re- 
sponses to phytohemagglutinin, pokeweed mitogen, and 
concanavalin A ( I  I ) .  
Cytotoxic drugs such as cyclophosphamide, chlo- 
rambucil, and azathioprine may induce leukopenia or 
thrombocytopenia. These complications have not been 
found in humans (5) treated with frentizole. Further- 
more, results of animal studies suggested that frentizole 
in immunosuppressive doses did not impair host resis- 
tance to bacterial, fungal, and viral infections as much 
as cytotoxic immunosuppressive drugs (6). In this re- 
spect, the absence of infections during and after frenti- 
zole therapy in the 1 1  SLE patients of this study may be 
noteworthy. 
Frentizole-associated hepatic toxicity was noted 
in 3 of the 1 1  patients who participated in this trial. The 
mechanism by which frentizole caused hepatotoxicity is 
unknown. This drug is metabolized rapidly by the liver 
( 12), and it is suspected that frentizole induces idiosyn- 
cratic hepatitis similar to that experienced by some pa- 
tients with SLE who take aspirin (13). No other toxic ef- 
fects were detected in this short-term trial. However, 
long-term use of frentizole in humans may lead to he- 
matologic, hepatic, or thyroid toxicity similar to that ob- 
served in animal toxicity studies. 
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